Related references
Note: Only part of the references are listed.Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin
Sumie Okahata et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus
Yoko Koike et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
No direct effect of SGLT2 activity on glucagon secretion
Rune E. Kuhre et al.
DIABETOLOGIA (2019)
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
Takayoshi Suga et al.
MOLECULAR METABOLISM (2019)
Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy
Robert Martinez et al.
DIABETES (2018)
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
Ryuzo Kawamori et al.
DIABETES OBESITY & METABOLISM (2018)
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
David Polidori et al.
DIABETES OBESITY & METABOLISM (2018)
Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study
Young-Gun Kim et al.
DIABETES OBESITY & METABOLISM (2018)
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
Wathik Alsalim et al.
DIABETES OBESITY & METABOLISM (2018)
CPR-IR is an insulin resistance index that is minimally affected by hepatic insulin clearance-A preliminary research
Tsuyoshi Okura et al.
PLOS ONE (2018)
Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
Hiroaki Ueno et al.
DIABETES THERAPY (2018)
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Paul Chi Ho Lee et al.
DIABETES THERAPY (2018)
Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
Hiroaki Ueno et al.
DIABETES THERAPY (2018)
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Paul Chi Ho Lee et al.
DIABETES THERAPY (2018)
Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
Francesco Prattichizzo et al.
DIABETES OBESITY & METABOLISM (2018)
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
John Wilding et al.
DIABETES THERAPY (2018)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials
Yumo Zhao et al.
DIABETES OBESITY & METABOLISM (2018)
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study
Takashi Shibuya et al.
DIABETES OBESITY & METABOLISM (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: comparison with commercially available immunoassays
Atsushi Miyachi et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2017)
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
Takashi Kadowaki et al.
DIABETES OBESITY & METABOLISM (2017)
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients
Hussein Al Jobori et al.
DIABETES OBESITY & METABOLISM (2017)
Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle
Tracy P. O'Brien et al.
DIABETES (2017)
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study
Thomas Forst et al.
DIABETES OBESITY & METABOLISM (2017)
Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay
Toshihiro Matsuo et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet
R. Nishimura et al.
DIABETES OBESITY & METABOLISM (2016)
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
Hisamitsu Ishihara et al.
DIABETES OBESITY & METABOLISM (2016)
Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents
Takahiro Oguma et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2016)
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study
R. Nishimura et al.
DIABETES OBESITY & METABOLISM (2015)
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients
Wakaba Tsuchimochi et al.
ENDOCRINE JOURNAL (2015)
POSTPRANDIAL DYNAMICS OF PLASMA GLUCOSE, INSULIN, AND GLUCAGON IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN ADD-ON TO METFORMIN THERAPY
Lars Hansen et al.
ENDOCRINE PRACTICE (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
B. Zambrowicz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Jian Chen et al.
Diabetes Therapy (2010)
SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes
Yuichiro Yamada et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Share Paper
